Skip to main content
HR 6294 115th Congress House

REVAMP Act

Official title: To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of priority antimicrobial products through the award of a transferable exclusivi… Show full official titleShow less

Official title: To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of priority antimicrobial products through the award of a transferable exclusivity extension period, and for other purposes.

Introduced: June 28, 2018 See on congress.gov
Health Advisory bodiesCongressional oversightDrug safety, medical device, and laboratory regulationDrug therapy
More subjectsShow fewer subjects
Government studies and investigationsHealth promotion and preventive careInfectious and parasitic diseasesIntellectual propertyLicensing and registrationsPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 28, 2018
Referred to the House Committee on Energy and Commerce.
Jun 28, 2018
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action June 28, 2018

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act

This bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a "priority antimicrobial product." (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6294: REVAMP Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-6294/
MLA
"H.R. 6294: REVAMP Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-6294/.
Bluebook (legal)
H.R. 6294, 115th Cong. (2026), https://openamerica.io/bill/115-HR-6294/.
Markdown link
[H.R. 6294: REVAMP Act](https://openamerica.io/bill/115-HR-6294/)
Report a problem